Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
Alamar Biosciences, Inc. (ALMR) P/E ratio
Alamar Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ALMR Alamar Biosciences, Inc. | n/m |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)